Abingdon Health PLC (GB:ABDX) has released an update.
Abingdon Health PLC reports a 52% revenue increase to £6.1m for FY24, with a significant reduction in EBITDA losses to £1.1m, signalling a strong year marked by strategic acquisitions and new product launches. The company, a leading CRO/CDMO specializing in lateral flow technology, has expanded its service offerings and anticipates further growth, having achieved a cashflow positive quarter in Q4-FY2024. Abingdon is well-positioned to continue its upward trajectory in the growing rapid diagnostic market.
For further insights into GB:ABDX stock, check out TipRanks’ Stock Analysis page.
